Free Trial

Anavex Life Sciences (AVXL) Competitors

Anavex Life Sciences logo
$9.01 0.00 (0.00%)
As of 02:03 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AVXL vs. APLS, AMRX, XENE, RARE, GMTX, CNTA, IMVT, TARS, CDTX, and MOR

Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Apellis Pharmaceuticals (APLS), AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Ultragenyx Pharmaceutical (RARE), Gemini Therapeutics (GMTX), Centessa Pharmaceuticals (CNTA), Immunovant (IMVT), Tarsus Pharmaceuticals (TARS), Cidara Therapeutics (CDTX), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

Anavex Life Sciences vs. Its Competitors

Anavex Life Sciences (NASDAQ:AVXL) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Anavex Life Sciences has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -30.24%. Anavex Life Sciences' return on equity of -45.67% beat Apellis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -45.67% -40.21%
Apellis Pharmaceuticals -30.24%-116.09%-26.72%

Anavex Life Sciences presently has a consensus target price of $44.00, suggesting a potential upside of 388.35%. Apellis Pharmaceuticals has a consensus target price of $33.47, suggesting a potential upside of 37.65%. Given Anavex Life Sciences' higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Apellis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Apellis Pharmaceuticals
2 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.47

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Apellis Pharmaceuticals had 17 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Apellis Pharmaceuticals and 1 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.65 beat Apellis Pharmaceuticals' score of 0.40 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Apellis Pharmaceuticals
6 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anavex Life Sciences has higher earnings, but lower revenue than Apellis Pharmaceuticals. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$43M-$0.57-15.81
Apellis Pharmaceuticals$781.37M3.93-$197.88M-$1.82-13.36

Anavex Life Sciences has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Summary

Anavex Life Sciences and Apellis Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVXL vs. The Competition

MetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$775.16M$3.41B$6.09B$10.52B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio-15.8322.6084.1427.05
Price / SalesN/A482.90607.44130.83
Price / CashN/A46.9737.8662.13
Price / Book6.3510.4012.236.56
Net Income-$43M-$52.47M$3.32B$276.75M
7 Day Performance-2.80%2.06%0.58%0.73%
1 Month Performance2.62%14.21%7.78%3.92%
1 Year Performance63.67%12.58%70.93%35.19%

Anavex Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVXL
Anavex Life Sciences
3.4528 of 5 stars
$9.01
flat
$44.00
+388.3%
+63.1%$775.16MN/A-15.8340
APLS
Apellis Pharmaceuticals
4.2826 of 5 stars
$24.14
-3.9%
$33.29
+37.9%
-13.6%$3.17B$781.37M0.00770Trending News
Analyst Forecast
Insider Trade
Analyst Revision
AMRX
AMNEAL PHARMACEUTICALS
2.9937 of 5 stars
$9.75
-2.2%
$12.00
+23.1%
+13.4%$3.13B$2.79B14.888,100
XENE
Xenon Pharmaceuticals
2.5193 of 5 stars
$39.99
+0.9%
$53.67
+34.2%
-1.1%$3.06B$9.43M0.00210News Coverage
Analyst Forecast
Options Volume
RARE
Ultragenyx Pharmaceutical
4.2931 of 5 stars
$32.02
+1.8%
$81.50
+154.5%
-41.1%$3.03B$560.23M0.001,294Trending News
Insider Trade
Analyst Revision
GMTX
Gemini Therapeutics
N/A$69.90
-1.2%
N/A+61.6%$3.03BN/A-69.9030
CNTA
Centessa Pharmaceuticals
3.4548 of 5 stars
$22.47
+0.7%
$32.38
+44.1%
+40.3%$2.99B$6.85M0.00200Insider Trade
IMVT
Immunovant
2.3567 of 5 stars
$17.35
+1.9%
$30.38
+75.1%
-40.3%$2.97BN/A0.00120Analyst Forecast
TARS
Tarsus Pharmaceuticals
1.1162 of 5 stars
$70.34
+0.3%
$66.67
-5.2%
+99.4%$2.96B$182.95M0.0050
CDTX
Cidara Therapeutics
3.9199 of 5 stars
$116.15
+2.7%
$146.50
+26.1%
+849.9%$2.87B$1.27M0.0090Analyst Forecast
Gap Down
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730

Related Companies and Tools


This page (NASDAQ:AVXL) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners